The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. - Wikidata - wikimedia - TriplyDB

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

http://www.wikidata.org/entity/Q41200962

about

The European Hematology Association Roadmap for European Hematology Research: a consensus document Utility of registries for post-marketing evaluation of medicines. A survey of Swedish health care quality registries from a regulatory perspective.Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013 Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia.Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.Obesity and related risk of myeloproliferative neoplasms among israeli adolescents.Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Management of pregnant chronic myeloid leukemia patients.Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study.A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.Prognostic discrimination based on the EUTOS long term survival score within the international registry for chronic myeloid leukemia in children and adolescents.Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries.The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Copy number variation analysis in cytochromes and glutathione S-transferases may predict efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia.Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012.Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.Chronic myeloid leukemia: room for improvement?Innovation in hematology. Perspectives: CML 2016 Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib.Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.Pregnancy: part of life in chronic myelogenous leukemia.

P2860

Q28830861-23067FDB-09F5-4E46-838F-B33462EE2620 Q33718413-B19EC9DD-06B9-40AD-B754-C3E569321792 Q35674595-3199D228-034A-4652-9FE4-74FF01D72909 Q35949910-BDFC80BF-7E70-4B35-ADDD-4C699B9C8C24 Q36288815-B8112FC2-6CE8-4CE0-B153-CE2B8BAAADE2 Q36442499-264EE4BC-A1B8-44F4-97EE-66C83D2F31FC Q37273788-846AC107-4937-4E20-9522-53E225D6FA27 Q38389475-B8A0539D-F0AE-4E76-967D-28E815668779 Q38620872-74BF0729-B216-4E77-8319-942CD297207A Q38684403-9CFE4EEA-2AD9-421D-B7E0-8DD530D0C187 Q38725366-076F5B23-6A40-4651-A10A-1BECB1325495 Q38845834-BF70438A-D0E0-48B7-B234-5E8CCBB680EE Q38879793-A8A53DF6-4CA7-4EDE-85F6-F7379CD87A16 Q38880265-3826AD82-BE40-4A22-B44A-77C4190B04BC Q39259447-BAA151BE-F141-4DEA-818C-80387CA9B490 Q39446340-6DA4A898-9822-491E-9008-9321AC4C3E3F Q39637488-9B31906F-7C83-4058-A71C-BBD7D0FC1CAB Q39924810-FE79AD6A-DE16-4506-AD8C-BC18AD5506DE Q40062215-AFBCFE12-44C9-4A32-AFC7-57CA02DE7630 Q40071286-ADA0A8B0-A659-4C06-8154-4A834B53F565 Q40294098-09249600-5933-4DB6-BA4E-757D2251B8BD Q40346616-534769C0-0BF9-466A-911B-F0256B3130D9 Q41144255-51AE0DD6-288A-469D-8B10-65C8A14DEFF1 Q41164222-0FB3A5C4-ECF4-4433-85A7-1C1F29975FD2 Q41293762-6FC7F8F0-5477-442A-8FBD-77779F9FC18B Q41348012-B75B00C8-2592-45FD-AF58-3F52622403D4 Q42316987-AC6E4A37-A4D2-4468-8CD4-80A9C6620568 Q42348447-29B085BE-04E0-4D89-AA84-0989ABEBF8A6 Q42397473-EEBF3977-4156-4D9A-BCFE-617D4ED43460 Q46461016-9D032BD9-5338-470E-ADE4-60762FC5A677 Q47413364-780BEA6D-B7D3-41BC-A896-316B1DFD6B1B Q48029219-5BD58473-B2FD-4961-B6C4-305629D23BD2 Q50976585-F23FDE65-D414-4AD2-8350-979FBD42C79F Q54186045-663AB4BA-74A9-437F-B429-1A4CFEE1FA03

P2860

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

http://www.wikidata.org/entity/Q41200962

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

The EUTOS population-based reg ...... ents in 20 European Countries.

@en

type

label

The EUTOS population-based reg ...... ents in 20 European Countries.

@en

prefLabel

The EUTOS population-based reg ...... ents in 20 European Countries.

@en

P1433

Q41200962-549A1273-11E2-4310-9358-3D1A82EA4D33

P1476

Q41200962-2023B601-7FD3-4BBC-BCF0-4EE36ECF869A

P2093

Q41200962-0350D31C-2D4F-41AC-B44A-4318B7B75A74

Q41200962-1424C264-F34F-4C4F-9AA9-CCE82300F3F6

Q41200962-2A3547D0-1680-4768-BBF9-44BA85686720

Q41200962-31E74F45-E1C3-40FB-823A-E763CAF9C837

Q41200962-3D49AFEB-1306-4B56-92F1-9FA7ACCE2278

Q41200962-456676D6-49C7-4D96-93E8-1034B955A00D

Q41200962-519D627D-5807-4543-BBEE-9F651176D168

Q41200962-6B65E724-8BB5-42A6-89F4-F8792D2BB8A9

Q41200962-819D4114-F26A-4215-8413-937EDC971618

Q41200962-84252CD1-73D0-4A51-A6A1-64D5B6D09D00

P2860

Q41200962-189FA262-2B13-4301-84E8-937FF2EEAD1F

Q41200962-1A21ED62-1D74-40C4-AF0B-9FE36A64F9DC

Q41200962-1B8F80C1-0C3B-45F6-8E7F-C1C9F51A6431

Q41200962-45E453EE-5517-4136-BDB3-C58B1B4C0424

Q41200962-49106E9C-3DEB-444C-9F9C-BD3A4177E0A2

Q41200962-4EBFF416-BE4F-48F6-8B6D-D9A9464770E4

Q41200962-5715F73B-136B-4C14-B204-A5A3D5F7E15B

Q41200962-58724C3B-B030-494E-8D5A-3B4850E2E0CA

Q41200962-5BAE9C4B-1E96-4CC6-BAF7-0A08E9799D00

Q41200962-6693C540-66D1-49CA-86C1-9588FBD81476

P2888

Q41200962-948113CA-D9B0-4AF7-B09A-90757E803AF8

P304

Q41200962-8381277C-AC05-4A1E-A0B6-3C02BB8473AE

P31

Q41200962-24B328D0-1773-495F-A2F7-FFF92F21A01E

P356

Q41200962-B0AAC9A8-E874-405C-BFF7-29C52870EB9D

P433

Q41200962-DE0CDC55-702E-47D9-93B5-77570A5FFDA3

P478

Q41200962-19044BA9-EF6E-44D9-A567-1DB89EB70C72

P50

Q41200962-6FEAE3DC-4216-4798-BE71-603D0EBC278C

Q41200962-8CA4938C-E741-4633-B362-964951BB87E2

Q41200962-BFC1B66F-22B9-48DD-9D69-C064A4399929

P577

Q41200962-9CAF0FCF-E0BA-4996-82AF-F8C42E2B62C4

P5875

Q41200962-67253B95-79C6-48D2-817F-070CC04A8B8F

P6179

Q41200962-6C56CA93-B843-4EEA-B078-1E44824B2549

P698

Q41200962-E6E2B576-66DA-461D-A4F9-3EDF4630EC03

P356

P1433

P1476

The EUTOS population-based reg ...... ients in 20 European Countries

@en

P2093

A Covelli

http://www.w3.org/2001/XMLSchema#string

A Hellmann

http://www.w3.org/2001/XMLSchema#string

A Zaritskey

http://www.w3.org/2001/XMLSchema#string

B Simonsson

http://www.w3.org/2001/XMLSchema#string

D Lindoerfer

http://www.w3.org/2001/XMLSchema#string

D Sertic

http://www.w3.org/2001/XMLSchema#string

F Castagnetti

http://www.w3.org/2001/XMLSchema#string

G Guidi

http://www.w3.org/2001/XMLSchema#string

G Schubert-Fritschle

http://www.w3.org/2001/XMLSchema#string

H Everaus

http://www.w3.org/2001/XMLSchema#string

P2860

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France)

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Chronic myeloid leukaemia.

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

P2888

P304

1336-1343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.73

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Di Raimondo

Andrija Bogdanovic

P577

2015-03-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273785584

http://www.w3.org/2001/XMLSchema#string

P6179

1043148566

http://www.w3.org/2001/XMLSchema#string

P698

25783795

http://www.w3.org/2001/XMLSchema#string